Back to Freepaper Session

Impact of prophylaxis with cefuroxime on cataract surgery

Session Details

Session Title: Inflammation

Session Date/Time: Tuesday 08/10/2013 | 16:30-18:00

Paper Time: 16:36

Venue: Auditorium (First Floor)

First Author: : C.Garcia-Saenz SPAIN

Co Author(s): :    A. Arias-Puente   G. Rodriguez-Caravaca   Y. Andres-Alba        

Abstract Details

Purpose:

To evaluate the clinical and economic impact of prophylactic administration of intracameral cefuroxime on cataract surgery

Setting:

Hospital Universitario Fundación Alcorcón

Methods:

Quasi-experimental study with before-after analysis. Consecutive patients who underwent cataract surgery between January 1999 and December 2012 were included. The evolution of the cumulative incidence of endophthalmitis before and after (October 2005) administration of intracameral cefuroxime as endophthalmitis prophylaxis in cataract surgery was studied. The annual incidence adjusting to a Poisson distribution was compared. The effectiveness of the prophylaxis was evaluated with the relative risk (RR). The impact of cefuroxime was evaluated with the attributable risk fraction and the number of patients needed to treat (NNT) to avoid a case of endophthalmitis.

Results:

Cataract surgery was carried out in 19463 patients, 6595 patients before and 12868 after October 2005. Endophthalmitis was diagnosed in 44 cases (39 before and 5 after). Positive microbiological cultures were obtained in 29 patients (66%). The overall cumulative incidence was 0.23 cases/100 patients. The RR was 0.06 (p < 0.05; 95%CI: 0.03 - 0.17), the impact or number needed to treat (NNT) was 182 and the attributable risk fraction was -0.93% (p < 0.05;95% CI: -0.82 - -0.97). The cost of a dose of cefuroxime was €1 and the cost of a case of endophthalmitis was €1358. The potential saving with cefuroxime was €1177 for every 182 patients treated.

Conclusions:

Intracameral cefuroxime reduced the incidence of endophthalmitis in cataract surgery and had a high clinical and economic impact on its prevention.

Financial Interest:

NONE